13,500 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,500 shares of the company’s stock, valued at approximately $101,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new position in shares of Recursion Pharmaceuticals during the second quarter worth approximately $302,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Recursion Pharmaceuticals by 39.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 49,863 shares of the company’s stock worth $374,000 after purchasing an additional 14,060 shares during the period. ARK Investment Management LLC raised its position in Recursion Pharmaceuticals by 14.5% during the 2nd quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock valued at $211,072,000 after purchasing an additional 3,555,357 shares in the last quarter. Liontrust Investment Partners LLP lifted its holdings in shares of Recursion Pharmaceuticals by 32.0% in the 2nd quarter. Liontrust Investment Partners LLP now owns 990,000 shares of the company’s stock worth $7,425,000 after buying an additional 240,000 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Recursion Pharmaceuticals by 20.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,060,804 shares of the company’s stock worth $7,956,000 after buying an additional 178,994 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

RXRX has been the subject of a number of research reports. Needham & Company LLC lowered their price objective on shares of Recursion Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, August 9th. KeyCorp dropped their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $8.42, for a total transaction of $421,000.00. Following the sale, the chief executive officer now owns 758,738 shares of the company’s stock, valued at approximately $6,388,573.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $8.45, for a total value of $96,727.15. Following the completion of the transaction, the director now directly owns 7,188,563 shares in the company, valued at $60,743,357.35. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $8.42, for a total transaction of $421,000.00. Following the transaction, the chief executive officer now directly owns 758,738 shares of the company’s stock, valued at $6,388,573.96. The disclosure for this sale can be found here. Insiders sold 255,682 shares of company stock valued at $1,990,912 in the last three months. 15.75% of the stock is owned by insiders.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $7.28 on Tuesday. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.97 and a 12-month high of $15.74. The business’s fifty day simple moving average is $7.50 and its 200-day simple moving average is $8.99. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.73 billion, a PE ratio of -4.55 and a beta of 0.83.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The business had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company’s quarterly revenue was up 30.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.38) earnings per share. Analysts expect that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.